ClinicalTrials.gg
Active, not recruitingNCT06076642Updated Apr 8, 2026

A Study About the Long-Term Safety of TAK-881 in People With Primary Immunodeficiency Diseases

A Phase 3 interventional study of TAK-881 and Koru 24 G HIgH Flo Subcutaneous Safety Needle Set (investigational in the US) in Primary Immunodeficiency Diseases (PID), sponsored by Takeda. Active, not recruiting at 25 sites in 7 countries. Open to participants aged 2 Years and older. Per ClinicalTrials.gov, last updated 2026-04-08.

Sponsored by Takeda · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
53
Allocation
Non-randomized
Ages
2 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 23 studies in Primary Immunodeficiency Diseases by Takeda — 2 open to participants now, 3 under way, 1 of them phase 3. Primary Immunodeficiency Diseases · Takeda.

Enrollment
8th of 18
53 · median 47
Started
2024
the only one that year
Phase 3
9 of 23
none open now
Registered
19th of 23
by date

Among the 23 studies in Primary Immunodeficiency Diseases by Takeda, this one is the 8th largest by enrollment of the 18 interventional ones that give a count, is the only one that started in 2024, is one of 9 in phase 3, and was the 19th registered.

Primary Immunodeficiency Diseases

211 studies on the registry are indexed under Primary Immunodeficiency Diseases; 51 are open to participants now.

Browse Primary Immunodeficiency Diseases studies →

Open to participants now

2 of the 23 studies in Primary Immunodeficiency Diseases by Takeda are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 35 Primary Immunodeficiency Diseases studies recruiting now, 12 (34%) set no upper age limit and 10 (29%) stop at 75 or younger; 28 take children under 18; 11 take healthy volunteers.

This study: 2 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies in Primary Immunodeficiency Diseases by Takeda, or all of them as a file.
02

Study summary

The main aim of this study is to learn if TAK-881 is safe and well tolerated during long-term use in adults and children with PIDD who are eligible and completed study TAK-881-3001 (NCT05755035).

The participants will receive the first dose of TAK-881 immunoglobulin (IgG) infusion at the same dosage as the last dose administered in study TAK-881-3001 (NCT05755035). After the first TAK-881 infusion in study TAK-881-3002, the dosing interval (can be adjusted by participant/caregiver) and/or the dose of TAK-881 can be adjusted by the study doctor to every 2, 3 or 4 weeks at scheduled site visits.

Participants will visit the clinic every 12 weeks until the End of Study (EOS) visit.

Read the detailed description

The study consists of two Epochs: Epoch 1 and Epoch 2. In Epoch 1 eligible participants will have the opportunity to receive TAK-881 for a minimum of 6 months. After 6 months in study TAK-881-3002, the results of the anti-rHuPH20 binding antibody assay from either study TAK-881-3001 (NCT05755035) or study TAK-881-3002 (Epoch 1) will be used to determine the next steps in the study:

  • Epoch 1: Participants with an anti-rHuPH20 antibody titer less than [\<] 1:160 will complete the EOS visit on the day of the first non-investigational product (IP) infusion following Study Visit Week 25.
  • Epoch 2: Participants with an anti-rHuPH20 antibody titer greater than or equal to [>=] 1:160 at any time point during Study TAK-881-3001 (NCT05755035) and/or study TAK-881-3002 (Epoch 1), will continue with an additional two years of TAK-881 treatment and undergo safety follow-up and will complete the EOS visit on the day of the first non-IP infusion following study Visit Week 121.
03

Conditions studied

  • Primary Immunodeficiency Diseases (PID)
04

Who can participate

Ages eligible
2 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Participants who meet ALL of the following criteria are eligible for this study:

  • Participant must have completed Study TAK-881-3001 (NCT05755035).
  • Participant or, in the case of minors, legally designated representative(s) is/are willing and able to comply with the requirements of the protocol.
  • Participant or, in the case of minors, legally designated representative(s) has/have provided /assent (if applicable), including providing consent for use of the medical device (in US sites only), prior to the initiation of any study procedures.

Exclusion criteria

Exclusion Criteria

  • Participant has a serious medical condition such that the participant's safety or medical care would be impacted by participation in this long-term follow-up study.
  • New medical condition that developed during participation in Study TAK-881-3001 (NCT05755035), that, in the judgment of the investigator, could increase risk to the participant or interfere with the evaluation of TAK-881 and/or conduct of the study.
  • Participant was enrolled in another clinical study involving an product (IP) or investigational device within 30 days prior to screening (with the exception of Study TAK-881-3001 [NCT05755035]).
  • Participant is scheduled to participate in another clinical study involving an IP or investigational device during the course of this study.
  • Participant is a family member or employee of the investigator or the investigator's site staff.
  • Participants with potential to become pregnant who meet any one of the following criteria:-

    1. Participant has a positive pregnancy test.
    2. Participant does not agree to employ a highly effective form of for the duration of the study.
  • If participant is pregnant or lactating at the time of screening or intends to become pregnant or begin lactating during the study.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
53 participants (actual)

Study arms

  • Experimental
    TAK-881

    Epoch 1: Participants who completed study TAK-881-3001 (NCT05755035) and met eligibility criteria will receive TAK-881 using Koru 24 G HlgH Flo subcutaneous (SC) safety needle set (investigational in the US) at the same dose and same treatment interval as at the last infusion in TAK-881-3001 (NCT05755035) at Week 1 and at Weeks 13 and Week 25 of study TAK-881-3002. Epoch 2: Participants with anti-rHuPH20 antibody titer \>=1:160 at any time point during Study TAK-881-3001 (NCT05755035) and/or Study TAK-881-3002 Epoch 1, will continue receiving TAK-881 every 12 weeks for up to Week 121. After the first TAK-881 infusion in study TAK-881-3002, the interval and/or the dose may be adjusted only at scheduled site visits at the investigator's discretion.

    Biological: TAK-881 · Device: Koru 24 G HIgH Flo Subcutaneous Safety Needle Set (investigational in the US)

Interventions

  • BiologicalTAK-881

    Participants will receive SC infusion of TAK-881.

    Also known as: Immune Globulin Subcutaneous (Human), 20% Solution with Recombinant Human Hyaluronidase (rHuPH20).

  • DeviceKoru 24 G HIgH Flo Subcutaneous Safety Needle Set (investigational in the US)

    The single-use only SC needle set will be used to administer TAK-881 to the target depth below the skin surface. One needle set (single or bifurcated) will be used per infusion.

06

What researchers measure

Primary outcomes

  1. Number of Participants With Treatment-Emergent Adverse Events (TEAEs)

    Time frame: Up to Week 121

  2. Number of Participants With Infusion Withdrawals, Interruptions, and Infusion Rate Reductions due to TAK-881-related TEAEs

    Time frame: Up to Week 121

Secondary outcomes

  1. Annualized Rate of all Infections

    Time frame: Up to Week 121

  2. Annualized Rate of Acute Serious Bacterial Infections (ASBIs)

    Time frame: Up to Week 121

  3. Annualized Rate of Episodes of Fever

    Time frame: Up to Week 121

  4. Time to First ASBI

    Time frame: Up to Week 121

  5. Duration of Infections

    Time frame: Up to Week 121

  6. Number of Participants With Positive Binding Antibodies and Neutralizing Antibodies to rHuPH20

    Time frame: Up to Week 121

  7. Trough Level of Total IgG

    Time frame: Up to Week 121

  8. Doses of TAK-881

    Time frame: Up to Week 121

  9. Treatment Interval of TAK-881

    Time frame: Up to Week 121

  10. Number of Infusions Per Month With TAK-881

    Time frame: Up to Week 121

  11. Number of Infusions Sites (Needle Sticks) per Month With TAK-881

    Time frame: Up to Week 121

  12. Number of Infusions Sites (Needle Sticks) per infusion With TAK-881

    Time frame: Up to Week 121

  13. Duration of Infusions (minutes) With TAK-881

    Time frame: Up to Week 121

  14. Monthly Infusion Time (minutes/month) With TAK-881

    Time frame: Up to Week 121

  15. Maximum Tolerated Infusion Rate per Site (milliliter/hour/site) With TAK-881

    Time frame: Up to Week 121

  16. Infusion Volume per Site (milliliter/site) With TAK-881

    Time frame: Up to Week 121

  17. Number of Participants who have Infusions of TAK-881 at Physical Location

    Physical location includes site/infusion center or home.

    Time frame: Up to Week 121

  18. Number of Participants, Caregiver, or Healthcare Professional (HCP) who have Administration of TAK-881

    Time frame: Up to Week 121

  19. Treatment Satisfaction Questionnaire for Medication (TSQM-9) Scores in Participants Aged >=16 Years

    TSQM-9 is a 9-item, validated, self-administered instrument to assess participants satisfaction with medication. It consists of 3 subscales: effectiveness, convenience and global satisfaction. The item scores of each of the 3 domains are summed and transformed to create a total score of 0 (extremely dissatisfied) to 100 (extremely satisfied). Higher score indicates greater satisfaction in that domain.

    Time frame: From Week 13 up to Week 121

  20. Health-Related Quality of Life (HRQoL): EuroQol 5 Dimension 5 Level Questionnaire (EQ-5D-5L) Score in Participants Aged >=12 Years

    The EQ-5D-5L is a validated, self-administered assessment of overall health designed by the EuroQol Group. The instrument consists of two components: the EQ-5D descriptive system and the standard vertical EQ visual analogue scale (EQ-VAS). The descriptive system consists of 5 dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression). Each dimension has five response categories: no problems, slight problems, some or moderate problems, severe problems, or extreme problems. Participants will be asked to describe their health state that day by choosing one of 5 responses that reflect the levels of severity for each of the 5 dimensions. The EQ-VAS measures one's self-perceived health today on a vertical scale from 0 (worst imaginable health) to 100 (best imaginable health) on which participants have to indicate their current health. Higher score indicates best health status.

    Time frame: From Baseline up to Week 121

  21. Treatment Preference Measured by a Disease-specific Questionnaire for TAK-881 in Participants Aged >=12 Years

    The disease-specific treatment preference questionnaire is a self-administered, non-validated scale to assess participant preference for various attributes of IgG therapy and accompanying devices, such as ease of use of administration of TAK-881 complexity of administration, and convenience. The questionnaire consists of two components. The first component asks participants to indicate the extent to which they like or dislike aspects of TAK-881, including treatment frequency, time, ease, convenience, and complexity. Each item has five response categories: like very much, like, no preference, dislike, and dislike very much. The second component is a single question asking whether they would choose to continue receiving treatment after the trial ends.

    Time frame: At Weeks 25 and 73

  22. Number of Days not Able to go to School, Work, Daycare, or to Perform Normal Daily Activities Due to Infections and/or their Treatment or Other Illnesses

    Time frame: Up to Week 121

  23. Number of Days on Antibiotics

    Time frame: Up to Week 121

  24. Number of Hospitalizations With Indications (Infection or other Illnesses)

    Time frame: Up to Week 121

  25. Number of Days of Hospitalization

    Time frame: Up to Week 121

  26. Number of Acute Physician Visits Due to Infection or Other Illnesses

    Time frame: Up to Week 121

  27. Infusion Preparation Time For TAK-881 by HCP

    Time frame: Up to Week 121

  28. Infusion Preparation Time For TAK-881 by Participants/Caregiver

    Time frame: Up to Week 121

07

Study locations

25 sites
  • University of California, Irvine Medical Sciences I
    Irvine, California 92697, United States
  • Allergy & Asthma Clinical Research
    Walnut Creek, California 94598, United States
  • National Jewish Medical And Research Center
    Denver, Colorado 80206-2761, United States
  • University of South Florida
    St. Petersburg, Florida 33701, United States
  • Central Georgia Infectious Disease Consultants
    Macon, Georgia 31201, United States
  • Rush University Medical Center-Allergy/ Immunology Center
    Chicago, Illinois 60612-3852, United States
  • Sneeze, Wheeze, & Itch Associates, LLC
    Normal, Illinois 61761, United States
  • Louisiana State University Health Science Center
    New Orleans, Louisiana 70118, United States
  • North Shore-Long Island Jewish Health Systems
    Great Neck, New York 11021, United States
  • Montefiore Medical Center
    The Bronx, New York 10461, United States
  • Duke Asthma, Allergy and Airway Center
    Durham, North Carolina 27705, United States
  • Allergy, Asthma and Immunology Center
    Tulsa, Oklahoma 74136, United States
  • Allergy Partners of North Texas
    Dallas, Texas 75230, United States
  • University Hospital Brno
    Brno, 62500, Czechia
  • Fakultni nemocnice Motol a Homolka Ustav imunologie
    Prague, 150 06, Czechia
  • Aarhus Universitetshospital
    Aarhus, 8200, Denmark
  • General Hospital of Thessaloniki
    Thessaloniki, 56429, Greece
  • Uniwersyteckie Centrum Kliniczne (UCK)
    Gdansk, 80-952, Poland
  • Osrodek Pediatryczny im. DR J. Korczaka, Wojewodzkie
    Lodz, 90329, Poland
  • Wojskowy Instytut Medyczny Panstwowy Instytut
    Warsaw, 04-141, Poland
  • Instytut Pomnik - Centrum Zdrowia Dziecka
    Warsaw, 04-730, Poland
  • NUDCH (National Institute of Childrens Diseases)
    Bratislava, 833 40, Slovakia
  • OKIA s.r.o
    Košice, 040 01, Slovakia
  • Klinika Deti a Dorastu - Odborne Ambulancie UNM a JLF UK
    Martin, 036 01, Slovakia
  • Hospital Sant Joan de Deu Barcelona
    Barcelona, 08950, Spain
08

References and documents

Individual participant data

Plan to share: Yes — Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Access criteria: IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/ For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.

Data sharing details ↗ · vivli.org

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2024 (actual). Primary completion is estimated for May 2028, 42 months after the start.

Of 25 phase 3 interventional studies under Primary Immunodeficiency Diseases, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 41. This study's planned 42 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 4, 2023
First posted
Oct 11, 2023
StartActual
Nov 4, 2024
Primary completionEst.
May 16, 2028
CompletionEst.
May 16, 2028
Last update
Apr 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 8, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06076642
Lead sponsor
Takeda
Collaborators
Takeda Development Center Americas, Inc., Baxalta Innovations GmbH, now part of Takeda
Responsible party
Sponsor
First posted
Oct 11, 2023
Start date
Nov 4, 2024
Primary completion
May 16, 2028 (estimated)
Completion
May 16, 2028 (estimated)
Last update
Apr 8, 2026

Study contacts

Study Director
study director · Takeda

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion